Document 3wxmyVq1noOzZoVZB4VKnkpy

| THERAPY Effect of Zinc Supplementation during Chelation with and without chelation therapy, in saturnism. therapy in Plumbism: A Case Report V.N. Finelli, S, Lemer, C. Hong, and G, Lohiya, MED LAV 1980 Mar-Apr; 71 (2):l49-56. Chelatable Lead Body Burden (by CalciumDisodium EDTA) and Blood Lead Concentration in Man Authors' summary: Chelation therapy with EDTA (ethylenediaminetetraacetic acid] for J.P. Hansen, M. Dossing, and P.E. Paulev, JOM 1981 Jan;23(l);39-43. elevated blood lead levels has been shown to be as Authors' abstract; The chelatable part of lead sociated with a marked increase in urinary excre body burden was measured in 32 workers and 7 tion of zinc and a decrease in plasma zinc levels office workers after an infusion test with and erythrocyte ALAD [aminolevulinic add dehy CaNa2EDTA. The workers had been exposed to dratase] activity. In this study, a worker with lead at a lead and zinc processing unit for 1 to 3 elevated blood lead levels was given oral zinc sup years (mean 1 year). There was good correlation (r plementation during EDTA chelation therapy. = 0.87) between blood lead and chelatable urinary During this treatment ALAD activity climbed lead excretion described by the equation y -- 0.07 fourfold to a peak on the last day of therapy. Blood lO0-48**. From this equation it can be predicted lead declined and urinary excretions of zinc and that the generally accepted limit value for chelata lead increased. Erythrocyte zinc remained un ble urinary lead excretion, 0.42 /xmol/mmol changed, whereas plasma zinc fell to 60% ofits pre CaNa2EDTA administered per 24 hours (3.1 treatment value. Although ALAD activity in umoI/24 hours or 650 ug/24 hours), corresponds creased during therapy, there was also an unex to a blood lead concentration (PbB) of 1.7 ^imol/1 plained increase of urinary ALA. No clinical side (or 35 /xg/100ml), which is lower than the com effects due to the treatment were observed in this monly accepted limit value of 2.9 /*mol/l (or 60 patient. Oral zinc supplementation, possibly in /xg/100ml) for ocoupationally lead-exposed per slightly augmented doses, appears to be a useful sons. There was a better correlation between the adjunct to EDTA therapy, since it elevates ALAD chelatable lead excretion and the urinary ALA activity and prevents severe depletion of body [aminolevulinic acid]-excretion (r = 0.45; p < zinc. These initial findings warrant further studies 0.001) than between PbB and the urinary ALA- ; to assess the beneficial aspects of zinc treatment, excretion (r = 0.26; p > 0,05). 1 ;i : I i'1, " ; 'Finelli VN, Lerner S, Hong C, Lohiya G: Effect of zinc 'Hansen JP, Dossing M> Paulev PE; Chelatable lead f, | supplementation during chelation therapy in plum- body burden (by calcium-disodium EDTA) and ' bism; a case report. MED LAV 1980 Mar- blood lead concentration in man. JOM 1981 Apr;71(2):149-56. Jan;23(l):39-43. Abstracted I I $ll % 1 I | % | ! 28 * QPO 1962 - 5U6-007ASU7, Regico h 44 Q172448224 DUP050032348 TEH 0531852